- Reference code :
- wf5340
- Published date :
-
25 July 2007
- Expired date :
-
10 December 2034
AstraZeneca today announced that Bo Angelin is to join the Board of Directors as a Non-Executive Director with immediate effect. Bo Angelin is currently Professor of Clinical Metabolism at Karolinska Institutet and Head of the Department of Endocrinology, Metabolism and Diabetes at the Karolinska University Hospital in Stockholm, Sweden, where his research group is studying the regulation of lipid metabolism in the liver by genes, diets, and hormones in order to find new ways of eliminating cholesterol from the body.
Louis Schweitzer, Chairman of AstraZeneca, said: “I am delighted that Bo Angelin has agreed to join us. His considerable experience in medical research and the practice of medicine will be of great benefit to the work of the Board”.
No disclosure obligations arise under paragraphs (1) to (6) of Listing Rule 9.6.13 of the UK Listing Authority’s Listing Rules in respect of the appointment of Bo Angelin.
Media Enquiries:
Steve Brown (London) +44 (0) 20 7304 5033
Edel McCaffrey (London) +44 (0) 20 7304 5034
Analyst/Investor Enquiries:
Jonathan Hunt (London) +44 (0) 20 7304 5087
Mina Blair (London) +44 (0) 20 7304 5084
Ed Seage (US) +1 302 886 4065
Jörgen Winroth (US) +1 212 579 0506
No disclosure obligations arise under paragraphs (1) to (6) of Listing Rule 9.6.13 of the UK Listing Authority’s Listing Rules in respect of the appointment of Bo Angelin.
Media Enquiries:
Steve Brown (London) +44 (0) 20 7304 5033
Edel McCaffrey (London) +44 (0) 20 7304 5034
Analyst/Investor Enquiries:
Jonathan Hunt (London) +44 (0) 20 7304 5087
Mina Blair (London) +44 (0) 20 7304 5084
Ed Seage (US) +1 302 886 4065
Jörgen Winroth (US) +1 212 579 0506
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
